Patients scheduled for gynecologic laparotomy
Conditions
Interventions
In remimazolam group, remiazolam administration is initiated at 12 mg/kg/h until patients lose their consciousness, and then is decreased at 1 mg/kg/h. The maintenace dose is at the discretion of atte
Sponsors
Hori Kotaro
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) Patients scheduled for genecologic laparatomy under general anesthesia 2) Patients aged 20 or older 3) Patients classified as ASA-PS 1 or 2 (American Society of Anesthesiologists-Physical Status) 4) Patients who fully understand the study after sufficient explanations and provide the written volun tary consent
Exclusion criteria
Exclusion criteria: 1) Patients who have contraindication or allergy to sevoflurane or remimazolam 2) Patients who have abnormal QT interval in preoperative ECG 3) Patients who do not have sinus rhythm in preoperative ECG 4) Patients who take antipsychotics, antiarrhythmics, or beta-blockers 5) Patients who have hypokalemia ( 5.5 mEq/L) in preoperative labor atory data 6) Patients whose BMI are 35 or greater 7) Patient who are considered ineligible for enrolling the study by a principal- or co-investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Heart-rate corrected QT (QTc) interval after tracheal extubation | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Correlation between plasma concentration of remimazolam and QTc 2) Correlation between plasma concentration of ropivacaine and QTc 3) QTc interval during induction of anesthesia 4) Hourly QTc inteval from the beggining to the end of surgery 5) QTc interval at postoperative day 1 6) Incidecne of perioperative fatal arrhythmia through medical record review | — |
Contacts
Public ContactKotaro Hori
Osaka Metropolitan University Graduate School of Medicine
Outcome results
None listed